FIELD: medicine, virology. SUBSTANCE: invention proposes vaccine for adults and children corresponding to an actual virus B/Peterburgh/92/95 by antigenic properties. Vaccine strain B/60/Peterburgh/95/20 is a reassortant obtained by breeding an epidemic virus B/Peterburgh/92/95 with cold-adapted temperature-sensitive viris B/USSR/60/69 - an attenuation donor. Strain is harmless for adults and children, its properties provide possibility to obtain reassortant vaccine strains from newly appearing epidemic viruses. Strain B/60/Peterburgh/95/20 multiplicates actively in developing chicken embryos at optimal temperature 32-33 C and shows temperature-sensitivity and cold-adaptation. Reassortant inherited two genes encoding surface proteins (hemagglutinin and neuraminidase) from an epidemic virus and six genes encoding nonglycosylated proteins from an attenuation donor. Strain B/60/Peterburgh is nonreactive for adults and children (3-14 years age) at intranasal administration and corresponds to immunogenicity indices. Vaccine strain B/60/Peterburgh/95/20 by its biological properties and reactive indices corresponds to requirements for vaccine strains by Pharmacopoeia articles FS 42-298 BS-89 and FS 42-299 VS-89 for living antiinfluenza vaccine for intranasal using for children (3-14 years age) and living antiinfluenza vaccine for intranasal using for adults. EFFECT: strain indicated above. 2 tbl, 2 ex
